SCHEMBL4532053

SCHEMBL4532053

NC(OCc1ccccc1)C1(C(=O)O)CCCCC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC1A1 P43005 5/20 0.51
SLC1A3 P43003 4/20 0.51
SLC1A2 P43004 4/20 0.51
MEN1 O00255 1/20 0.51
CYP1A2 P05177 1/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
KMT2A Q03164 1/20 0.51
CTSL P07711 1/20 0.38
CTSB P07858 1/20 0.38
CTSS P25774 1/20 0.38
ALDH1A1 P00352 3/20 0.37
AKR1C1 Q04828 1/20 0.37
ALPI P09923 1/20 0.37
PKM P14618 1/20 0.37
PTGS1 P23219 1/20 0.37
XIAP P98170 1/20 0.37
SLC7A5 Q01650 1/20 0.37
ADRB2 P07550 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4866841 1.00 SLC1A1 (0.51) SLC1A1SLC1A3SLC1A2MEN1CYP1A2
SCHEMBL4866933 0.98 SLC1A1 (0.53) SLC1A1SLC1A3SLC1A2MEN1CYP1A2
SCHEMBL6232780 0.86 SLC1A1 (0.49) SLC1A1SLC1A3SLC1A2MEN1CYP1A2
SCHEMBL21046167 0.82 SLC1A3 (0.44) SLC1A1SLC1A3SLC1A2MEN1CYP1A2
SCHEMBL6204613 0.81 SLC1A3 (0.43) SLC1A1SLC1A3SLC1A2MEN1CYP1A2
SCHEMBL6237656 0.78 SLC1A1 (0.47) SLC1A1SLC1A3SLC1A2MEN1CYP1A2
SCHEMBL9485706 0.77 ALPI (0.47) SLC1A1SLC1A3SLC1A2CYP1A2ALPI
SCHEMBL10418944 0.74 ALDH1A1 (0.45) ALDH1A1
SCHEMBL10718992 0.74 SLC1A3 (0.42) SLC1A1SLC1A3SLC1A2MEN1CYP1A2
SCHEMBL26961850 0.73 SLC1A2 (0.46) SLC1A1SLC1A3SLC1A2MEN1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090318445-A1 PDF INHIBITORS NORVARTIS AG (CH) 2009-12-24 US disclosed
US-7332485-B2 Peptide deformylase inhibitors SMITHKLINE BEECHAM CORP (US) 2008-02-19 US disclosed
US-20060160802-A1 Peptide deformylase inhibitors GLAXO GROUP LIMITED 2006-07-20 US disclosed
WO-2005005456-A2 PEPTIDE DEFORMYLASE INHIBITORS GLAXO GROUP LIMITED (GB) 2005-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318445-A1 PDF INHIBITORS PDF, TIMP3, MMP2 SLC1A1 3596/4885SLC1A3 3794/4885SLC1A2 4344/4885
US-20060160802-A1 Peptide deformylase inhibitors PDF, PEPD, DPEP1 SLC1A1 3802/4885SLC1A3 3318/4885SLC1A2 4306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.